NCT04401423View on ClinicalTrials.gov

TXA127 for the Treatment of Severe COVID-19

PHASE2CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions

COVID-19

Interventions

DRUG

TXA127

0.5 mg/kg per day

DRUG

Placebo

0.5 mg/kg per day

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Constant Therapeutics LLC

All Listed Sponsors

collaborator

Constant Therapeutics LLC

INDUSTRY

lead

Columbia University

OTHER